EMA Recommends Granting a Marketing Authorisation for Lurbinectedin By Ogkologos - April 30, 2026 109 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Promising Results Demostrated with Novel Subcutaneously Adminstered Envafolimab in Patients with... November 20, 2020 Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic... May 12, 2021 Factors Associated with COVID-19 Severity Among Patients with Cancer March 22, 2021 Changing the landscape of children’s cancer treatment September 2, 2020 Load more HOT NEWS People with Intellectual Disability at Increased Risk of Cancer Study Links Non-Diet Soda Consumption with a Higher Risk of Death... Promising Results Demostrated with Novel Subcutaneously Adminstered Envafolimab in Patients with... ASCO Annual Meeting 2023: Adding Durvalumab and Olaparib to Treatment Delays...
